Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma

Pediatr Allergy Immunol. 2014 Dec;25(8):829-32. doi: 10.1111/pai.12306. Epub 2014 Dec 18.
No abstract available

Keywords: asthma; omalizumab; subcutaneous allergen-specific immunotherapy.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Anti-Idiotypic / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Asthma / immunology
  • Asthma / therapy*
  • Child
  • Desensitization, Immunologic / methods*
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Humans
  • Injections, Subcutaneous
  • Male
  • Omalizumab
  • Rhinitis, Allergic / immunology
  • Rhinitis, Allergic / therapy*
  • Treatment Outcome
  • Young Adult

Substances

  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal, Humanized
  • Omalizumab